TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6134048

Group type: EXPERIMENTAL
Intervention: Exclusion diets and provocation tests
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patients with confirmed food hypersensitivity
Number of subjects: 23

Group type: COMPARATOR
Intervention: Patients whose belief in food allergy could not be confirmed
Number of subjects: 23
Study: 30947107

Group type: EXPERIMENTAL
Intervention: High intensity functional anaerobic and progressive resistance training of the lower limbs (n = 8)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Waitlist control group (n = 9)
Number of subjects: 17
Study: 28492790

Group type: EXPERIMENTAL
Intervention: rhBNP (0.005 µg kg‐1 min‐1 for 72 hours)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (standard therapy only)
Number of subjects: 48
Study: 26199182

Group type: EXPERIMENTAL
Intervention: 3-day DEX
Number of subjects: 116

Group type: COMPARATOR
Intervention: 1-day DEX
Number of subjects: 116
Study: 23621906

Group type: EXPERIMENTAL
Intervention: Autologous blood injection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Steroid injection
Number of subjects: 50
Study: 22082239

Group type: COMPARATOR
Intervention: Usual care (quarterly PCP visits with education about weight management)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Brief lifestyle counseling (quarterly PCP visits + brief monthly sessions with lifestyle coaches)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Enhanced brief lifestyle counseling (same as brief lifestyle counseling + meal replacements or weight-loss medication)
Number of subjects: 390
Study: 19463202

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate, 110 mug q.d. for 4 weeks
Number of subjects: 699

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 699
Study: 16501036

Group type: EXPERIMENTAL
Intervention: Intranasal E2/NETA [175 microg/275 microg]
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral E2/NETA [1 mg/0.5 mg]
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 15545881

Group type: EXPERIMENTAL
Intervention: Posttherapy scanning on first ablation
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Posttherapy scanning
Number of subjects: 106
Study: 10675118

Group type: EXPERIMENTAL
Intervention: Educational programme based on clinical-practice guideline
Number of subjects: 4192

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 4192
Study: 9095401

Group type: EXPERIMENTAL
Intervention: Vigabatrin (150 mg/kg per day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Hydrocortisone (15 mg/kg per day)
Number of subjects: 22
Study: 1311650

Group type: EXPERIMENTAL
Intervention: Subpressor dose of angiotensin II (3 ng min‐1 kg‐1 for 15 min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Subpressor dose of angiotensin II (3 ng min‐1 kg‐1 for 15 min) during handgrip exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pressor dose of angiotensin II (13 ng min‐1 kg‐1 for 15 min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pressor dose of angiotensin II (13 ng min‐1 kg‐1 for 15 min) during isometric exercise
Number of subjects: 8
Study: 4017672

Group type: EXPERIMENTAL
Intervention: Theophylline (4 mg/kg twice daily for three days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31186395

Group type: EXPERIMENTAL
Intervention: DynaCT+DSA treatment group (27 cases)
Number of subjects: 57

Group type: COMPARATOR
Intervention: DSA treatment group (30 cases)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: DynaCT+DSA treatment group
Number of subjects: 57

Group type: COMPARATOR
Intervention: DSA treatment group
Number of subjects: 57
Study: 30178733

Group type: EXPERIMENTAL
Intervention: Prospective Subjective Memory Complaints (SMCs)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Retrospective Subjective Memory Complaints (SMCs)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Depressive symptoms and poor quality of life
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: PRMQ (Prospective and Retrospective Memory Questionnaire)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Self-reported memory problems
Number of subjects: 560
Study: 28301177

Group type: EXPERIMENTAL
Intervention: Deontologists in social dilemma games
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deontologists in public goods games
Number of subjects: 0

Group type: COMPARATOR
Intervention: Consequentialists in social dilemma games
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deontologists in trust games
Number of subjects: 0
Study: 26254984

Group type: EXPERIMENTAL
Intervention: Aspiration of pus
Number of subjects: 53

Group type: COMPARATOR
Intervention: Wait-and-see policy
Number of subjects: 53
Study: 23280682

Group type: EXPERIMENTAL
Intervention: Propensity Score Matching
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Propensity Score Weighting
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Propensity Score Weighting after excluding extreme observations
Number of subjects: 1292
Study: 21565848

Group type: EXPERIMENTAL
Intervention: AC‐RCT participants (579 patients)
Number of subjects: 1242

Group type: COMPARATOR
Intervention: Non-participants (663 patients)
Number of subjects: 1242
Study: 18474494

Group type: EXPERIMENTAL
Intervention: LPV/r + FPV
Number of subjects: 56

Group type: COMPARATOR
Intervention: LPV/r or FPV + r
Number of subjects: 56
Study: 16634531

Group type: EXPERIMENTAL
Intervention: Contractubex®
Number of subjects: 859

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 859
Study: 12910523

Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel (C/P) for 4 cycles (AUC of 6 for carboplatin and 200 mg/m2 for paclitaxel every 21 days)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel (C/P)
Number of subjects: 230
Study: 11099872

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transdermic 17 beta‐estradiol at 50 microg per day
Number of subjects: 0
Study: 9259219

Group type: EXPERIMENTAL
Intervention: Short cognitive behavioural group therapy programme focused on patient education and stress relaxation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of untreated patients.
Number of subjects: 0
Study: 8318322

Group type: EXPERIMENTAL
Intervention: Extradural clonidine 450 micrograms
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Extradural clonidine 450 micrograms plus oral yohimbine 16 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3522003

Group type: EXPERIMENTAL
Intervention: Dopamine (6.2 +/- 1.7 micrograms/kg/min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dobutamine (6.7 +/- 2.5 micrograms/kg/min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison of dopamine and dobutamine
Number of subjects: 9
Study: 29385644

Group type: EXPERIMENTAL
Intervention: Partial-mouth recording (PMR) protocols
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Modified PMR protocols
Number of subjects: 640
Study: 26846934

Group type: EXPERIMENTAL
Intervention: Hip arthroscopy with or without labral repair
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physical therapy (2 sessions per week for 6 weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (hip arthroscopy and physical therapy)
Number of subjects: 80
Study: 25137867

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 90

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 90

Group type: COMPARATOR
Intervention: Fiberoptic bronchoscope
Number of subjects: 90
Study: 23529771

Group type: COMPARATOR
Intervention: Night Float (NF) model
Number of subjects: 43

Group type: COMPARATOR
Intervention: Q5 model (every fifth night overnight call)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Q5 model
Number of subjects: 43

Group type: COMPARATOR
Intervention: NF model
Number of subjects: 43

Group type: COMPARATOR
Intervention: 2003-compliant model (control)
Number of subjects: 43
Study: 20388468

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pragmatic randomized controlled trial (PRCT)
Number of subjects: 0
Study: 17943371

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Staples (SG)
Number of subjects: 22
Study: 16639677

Group type: EXPERIMENTAL
Intervention: Heparin-coated ECC circuits (group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Uncoated ECC circuits (group B)
Number of subjects: 28
Study: 14583417

Group type: COMPARATOR
Intervention: Placebo (4 alfalfa capsules per day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low-dose kelp (2 kelp capsules and 2 alfalfa capsules per day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-dose kelp (4 kelp capsules per day)
Number of subjects: 36
Study: 10981244

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 1000

Group type: COMPARATOR
Intervention: No ACE inhibitors
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: ACE inhibitors in hypertensive patients
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: ACE inhibitors in normotensive patients
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: ACE inhibitors usage over time
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: ACE inhibitors in patients with adverse renal outcomes
Number of subjects: 1000
Study: 7643882

Group type: COMPARATOR
Intervention: Heparin (10,000 IU bolus followed by intravenous infusion for 24 hours and subcutaneous placebo twice daily for three days)
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: Intravenous hirudin (40 mg bolus followed by intravenous infusion for 24 hours and subcutaneous placebo twice daily for three days)
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: Intravenous and subcutaneous hirudin (40 mg bolus followed by intravenous infusion for 24 hours and subcutaneous hirudin twice daily for three days)
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: Hirudin (combined group of intravenous and subcutaneous)
Number of subjects: 1141

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: Intravenous hirudin
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1141
Study: 2539286

Group type: EXPERIMENTAL
Intervention: 60% carbohydrate diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: 40% carbohydrate diet
Number of subjects: 0
Study: 319698

Group type: EXPERIMENTAL
Intervention: Nonabsorbable subcuticular sutures
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Absorbable subcuticular sutures
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (superior and inferior portions of the scar)
Number of subjects: 17
Study: 31124299

Group type: EXPERIMENTAL
Intervention: iGlarLixi (insulin glargine 100 U and lixisenatide)
Number of subjects: 859

Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 859

Group type: COMPARATOR
Intervention: Lixi
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 859
Study: 27800565

Group type: EXPERIMENTAL
Intervention: Six PA SMS/week
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard T4b SMS
Number of subjects: 80
Study: 26124653

Group type: EXPERIMENTAL
Intervention: Indacaterol
Number of subjects: 82

Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 82
Study: 24244272

Group type: EXPERIMENTAL
Intervention: Online video of diagnosis-specific discharge instructions
Number of subjects: 133

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 133
Study: 20831368

Group type: EXPERIMENTAL
Intervention: Locally delivered doxycycline (8.8% doxycycline gel) as an adjunct to mechanical debridement
Number of subjects: 32

Group type: COMPARATOR
Intervention: Mechanical debridement only (control group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Locally delivered doxycycline
Number of subjects: 32
Study: 18435949

Group type: EXPERIMENTAL
Intervention: Post-PCI hyperemic flow (CTFC<14)
Number of subjects: 3491

Group type: COMPARATOR
Intervention: Normal flow (CTFC 14 to 28)
Number of subjects: 3491
Study: 17152037

Group type: EXPERIMENTAL
Intervention: Cephazolin prophylaxis
Number of subjects: 303

Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 303
Study: 14614668

Group type: EXPERIMENTAL
Intervention: artesunate-chloroquine (group 1)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: artesunate-sulfadoxine-pyrimethamine (group 2)
Number of subjects: 123
Study: 10924313

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (n=84)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Sinus rhythm (n=325)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: New onset atrial fibrillation (n=30)
Number of subjects: 409
Study: 9412078

Group type: EXPERIMENTAL
Intervention: Extrusion products 'Jantar' containing 10% dietary fiber gumarabic
Number of subjects: 0
Study: 8458181

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propranolol 120 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3755608

Group type: EXPERIMENTAL
Intervention: CQP201-403 (0.025 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 28745520

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Attention control (HF self-management education)
Number of subjects: 51
Study: 29915869

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diffuser mask (OxyMask)
Number of subjects: 60
Study: 27733405

Group type: EXPERIMENTAL
Intervention: No-carbohydrate breakfast
Number of subjects: 45

Group type: COMPARATOR
Intervention: Carbohydrate breakfast
Number of subjects: 45
Study: 24246414

Group type: EXPERIMENTAL
Intervention: 78 Gy
Number of subjects: 664

Group type: COMPARATOR
Intervention: 68 Gy
Number of subjects: 664
Study: 22563751

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 110
Study: 20974324

Group type: EXPERIMENTAL
Intervention: Test formulation of Clopidogrel bisulfate (300 mg on day 1, then 75 mg for 6 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reference formulation of Clopidogrel bisulfate (300 mg on day 1, then 75 mg for 6 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Test formulation of Clopidogrel bisulfate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reference formulation of Clopidogrel bisulfate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 30
Study: 18607941

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SNB)
Number of subjects: 35
Study: 16045502

Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the left M1
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS of the left M1
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 16
Study: 11854741

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced duplex scanning using sulphur hexafluoride (SF(6))
Number of subjects: 14
Study: 10939028

Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pravastatin 10 mg/day
Number of subjects: 0
Study: 8777116

Group type: EXPERIMENTAL
Intervention: Propofol administered intravenously over 15 seconds to premedicated children with midazolam
Number of subjects: 110

Group type: COMPARATOR
Intervention: Propofol administered intravenously over 15 seconds to unpremedicated children
Number of subjects: 110
Study: 1497159

Group type: EXPERIMENTAL
Intervention: Minidose succinylcholine (0.1 mg/kg) IV
Number of subjects: 46

Group type: COMPARATOR
Intervention: Pancuronium (0.03 mg/kg) IV
Number of subjects: 46
Study: 6369006

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 207

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 207
Study: 30368021

Group type: EXPERIMENTAL
Intervention: Exercise (measured by Fitbit activity)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Baseline sleep quality (PSQI > 5)
Number of subjects: 32
Study: 30148646

Group type: EXPERIMENTAL
Intervention: 4-week intervention program to improve landing techniques through strength and plyometric training 3 times a week
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 4-week intervention program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (regular training only)
Number of subjects: 40
Study: 27053769

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vasopressin (AVP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24222194

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 991

Group type: COMPARATOR
Intervention: Capecitabine plus lapatinib
Number of subjects: 991
Study: 22587345

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 150 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Glimepiride 1-2 mg
Number of subjects: 3
Study: 20979470

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 5059

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5059
Study: 19334373

Group type: EXPERIMENTAL
Intervention: CD34+ hemopoietic precursor and stem cells (HPC) in celiac patients (Group B)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (Group A) of healthy subjects
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Celiac patients (Group B)
Number of subjects: 28
Study: 16043939

Group type: EXPERIMENTAL
Intervention: Regimen 1: All antihypertensive agents given once a day in the morning
Number of subjects: 15

Group type: COMPARATOR
Intervention: Regimen 2: All antihypertensive agents given in the morning, except the CCB which was given at 4:00 pm
Number of subjects: 15
Study: 11812685

Group type: EXPERIMENTAL
Intervention: Weight-based aprotinin dosing schedule
Number of subjects: 40

Group type: COMPARATOR
Intervention: Full-dose aprotinin regimen
Number of subjects: 40
Study: 10520404

Group type: EXPERIMENTAL
Intervention: EE/CPA (2 mg cyproterone acetate and 0.035 mg ethinyloestradiol)
Number of subjects: 890
Study: 7582304

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Domiciliary oxygen
Number of subjects: 26

Group type: COMPARATOR
Intervention: Domiciliary air
Number of subjects: 26
Study: 1936012

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 40 mg t.i.d.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Molsidomine 8 mg t.i.d.
Number of subjects: 10
Study: 7423136

Group type: EXPERIMENTAL
Intervention: Euphyllin retard (theophylline slow‐releasing coated tablets)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31819405

Group type: EXPERIMENTAL
Intervention: Erdosteine 300 mg twice daily (n=126)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo (n=128)
Number of subjects: 254
Study: 28186618

Group type: EXPERIMENTAL
Intervention: Prior fall
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Dementia
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Registered nurses
Number of subjects: 433

Group type: COMPARATOR
Intervention: Black resident photo
Number of subjects: 433
Study: 25671655

Group type: EXPERIMENTAL
Intervention: Education and PMR
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Education plus PMR
Number of subjects: 64

Group type: COMPARATOR
Intervention: Education
Number of subjects: 64

Group type: COMPARATOR
Intervention: PMR
Number of subjects: 64
Study: 23897967

Group type: EXPERIMENTAL
Intervention: Structured intervention (informational pamphlet and discussion)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 120
Study: 22337213

Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 1684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1684
Study: 19406488

Group type: EXPERIMENTAL
Intervention: Multidisciplinary clinic intervention
Number of subjects: 45
Study: 17374706

Group type: EXPERIMENTAL
Intervention: Oral ethinyl estradiol (15 microg/d)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Vaginal ethinyl estradiol (15 microg/d)
Number of subjects: 14
Study: 15798304

Group type: EXPERIMENTAL
Intervention: Non-invasive measurement of intrapulmonary shunt using oxygen uptake and pulmonary capillary blood flow measurement obtained by nitrous oxide rebreathing
Number of subjects: 9

Group type: COMPARATOR
Intervention: Invasive standard measurement using mixed venous blood sampling
Number of subjects: 9
Study: 12466695

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (PSE) 120 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9651906

Group type: COMPARATOR
Intervention: Pravastatin alone (M group)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Pravastatin and hormone replacement therapy (HRT) (MC group)
Number of subjects: 57
Study: 8209274

Group type: EXPERIMENTAL
Intervention: Mitomycin/ifosfamide/cisplatin chemotherapy plus surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 3057850

Group type: EXPERIMENTAL
Intervention: atenolol 50 or 100 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: nadolol 40 or 80 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: nadolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: both beta blockers
Number of subjects: 16
Study: 29283099

Group type: EXPERIMENTAL
Intervention: Group 1 (G1) - Patients with unilateral SNHL and unilateral non-pulsatile tinnitus
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Group 2 (G2) - Patients with normal hearing and unilateral non-pulsatile tinnitus
Number of subjects: 3

Group type: COMPARATOR
Intervention: Group 3 (G3) - Healthy volunteers with neither tinnitus nor hearing loss
Number of subjects: 3